Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer patients: do pre-transplant drugs improve outcomes?

NCT ID NCT07418138

Knowledge-focused Sponsor: Hu Liangshuo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, cancer recurrence, and liver function after surgery. The goal was to find out what factors affect patient outcomes after a liver transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

484 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (age 18 or older) who underwent LT using grafts from deceased donors between January 1st, 2015, and December 31st, 2024, were retrospectively identified using the China Liver Transplant Registry (CLTR) and clinical data in the First Affiliated Hospital of Xi'an Jiaotong University

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years; 2. HCC diagnosis confirmed through imaging and elevated serum alpha-fetoprotein (AFP); 3. Underwent liver transplantation for hepatocellular carcinoma. 4. Underwent primary (first-time) liver transplantation. 5. Availability of complete clinical and follow-up data for analysis. Exclusion Criteria: 1. age \<18 years or \>75 years; 2. living-donor liver transplantation or re-transplantation; 3. concurrent active malignancy other than HCC; 4. incomplete key baseline data or follow-up information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC) Liver transplantation Survival rate Tyrosine kinase inhibitor

Contacts and locations

Locations

  • First Affiliated Hospital Xian Jiaotong University

    Xi'an, Shaanxi, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.